{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,12,19]],"date-time":"2025-12-19T21:03:20Z","timestamp":1766178200864,"version":"3.48.0"},"reference-count":41,"publisher":"American Society of Clinical Oncology (ASCO)","content-domain":{"domain":["ascopubs.org"],"crossmark-restriction":true},"short-container-title":["JCO Oncol Pract"],"abstract":"<jats:sec>\n                    <jats:title>PURPOSE<\/jats:title>\n                    <jats:p>The OVHIPEC-1 trial demonstrated that adding hyperthermic intraperitoneal chemotherapy (HIPEC) to interval cytoreductive surgery (CRS) for patients with stage III epithelial ovarian cancer results in a significant increase in recurrence-free survival and overall survival. To inform policymakers about the macroeconomic budget, we conducted a budget impact analysis.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>METHODS<\/jats:title>\n                    <jats:p>The expenditure of the Dutch health care system between 2017 and 2025 associated with the introduction of HIPEC for patients with stage III ovarian cancer eligible for interval CRS (target population) was assessed during their entire treatment course (surgical and subsequent treatment). Cost estimates are based on national registry data, national benchmark costs for hospital-related activities, list prices for drugs, therapeutic guidelines, and expert opinion. Sensitivity and scenario analyses were performed to test robustness of the analysis.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>RESULTS<\/jats:title>\n                    <jats:p>The Dutch target population is expected to increase from 200 patients in 2017 to 233 patients in 2025, with 80% receiving HIPEC in 2025. Between 2017 and 2025, the impact on the annual surgical budget is \u20ac3.5 million, of which \u20ac1.8 million is directly attributable to HIPEC and its associated costs. When considering the cost of all ovarian cancer\u2013related treatments, an additional \u20ac30,898 per HIPEC patient is spent in 2025, mainly driven by prolonged recurrence-free survival resulting in extended maintenance therapy and treatment for more platinum-sensitive recurrences. This leads to an annual total treatment budget impact of \u20ac26 million in 8 years, with \u20ac5.7 million directly associated with HIPEC use.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>CONCLUSION<\/jats:title>\n                    <jats:p>Within the Dutch health care system, the surgical budget impact of HIPEC is acceptable and falls within the boundaries for reimbursement of the responsible decision-making bodies. The total budget impact is mostly affected by the high costs of systemic treatment after prolonged recurrence-free survival due to HIPEC.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1200\/op-25-00670","type":"journal-article","created":{"date-parts":[[2025,12,19]],"date-time":"2025-12-19T20:59:48Z","timestamp":1766177988000},"update-policy":"https:\/\/doi.org\/10.1200\/crossmark","source":"Crossref","is-referenced-by-count":0,"title":["Budget Impact Analysis of Hyperthermic Intraperitoneal Chemotherapy With Interval Cytoreductive Surgery in Ovarian Cancer"],"prefix":"10.1200","author":[{"ORCID":"https:\/\/orcid.org\/0009-0008-8079-853X","authenticated-orcid":true,"given":"Madelief","family":"Schreuder Goedheijt","sequence":"first","affiliation":[{"name":"Department of Gynecological Oncology, The Netherlands Cancer Institute\u2014Antoni van Leeuwenhoek Hospital, Amsterdam, the Netherlands"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ruby M.","family":"van Stein","sequence":"additional","affiliation":[{"name":"Department of Gynecological Oncology, The Netherlands Cancer Institute\u2014Antoni van Leeuwenhoek Hospital, Amsterdam, the Netherlands"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Simone N.","family":"Koole","sequence":"additional","affiliation":[{"name":"Department of Gynecological Oncology, The Netherlands Cancer Institute\u2014Antoni van Leeuwenhoek Hospital, Amsterdam, the Netherlands"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8088-9628","authenticated-orcid":true,"given":"Gabe S.","family":"Sonke","sequence":"additional","affiliation":[{"name":"Department of Medical Oncology, Netherlands Cancer Institute\u2014Antoni van Leeuwenhoek Hospital, Amsterdam, the Netherlands"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2246-1994","authenticated-orcid":true,"given":"Willemien J.","family":"van Driel","sequence":"additional","affiliation":[{"name":"Department of Gynecological Oncology, The Netherlands Cancer Institute\u2014Antoni van Leeuwenhoek Hospital, Amsterdam, the Netherlands"},{"name":"Center for Gynecological Oncology Amsterdam, Netherlands Cancer Institute, Amsterdam, the Netherlands"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5624-3234","authenticated-orcid":true,"given":"Valesca P.","family":"Ret\u00e8l","sequence":"additional","affiliation":[{"name":"Division of Psychosocial Research and Epidemiology, Netherlands Cancer Institute\u2014Antoni van Leeuwenhoek Hospital, Amsterdam, the Netherlands"},{"name":"Erasmus School of Health Policy and Management, Erasmus University Rotterdam, Rotterdam, the Netherlands"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"233","published-online":{"date-parts":[[2025,12,19]]},"reference":[{"key":"e_1_3_8_2_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejca.2017.10.030"},{"key":"e_1_3_8_3_2","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2016.68.6907"},{"key":"e_1_3_8_4_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1708618"},{"key":"e_1_3_8_5_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejso.2019.05.006"},{"key":"e_1_3_8_6_2","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.19.00594"},{"key":"e_1_3_8_7_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.jval.2013.08.2291"},{"key":"e_1_3_8_8_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejso.2021.01.019"},{"key":"e_1_3_8_9_2","unstructured":"Zorginstituut Nederland (ZiNL): Standpunt hyperthermic intraperitoneal chemotherapy (HIPEC) toegevoegd aan interval debulking bij stadium III ovariumcarcinoom [in Dutch] 2018. https:\/\/www.zorginstituutnederland.nl\/publicaties\/standpunten\/2018\/12\/11\/standpunt-hyperthermic-intraperitoneal-chemotherapy-hipec-toegevoegd-aan-interval-debulking-bij-stadium-iii-ovariumcarcinoom"},{"key":"e_1_3_8_10_2","unstructured":"Zorginstituut Nederland (ZiNL): Kostenhandleiding voor economische evaluaties in de gezondheidszorg: Methodologie en Referentieprijzen [in Dutch] 2015. https:\/\/www.zorginstituutnederland.nl\/documenten\/2024\/01\/16\/richtlijn-voor-het-uitvoeren-van-economische-evaluaties-in-de-gezondheidszorg"},{"key":"e_1_3_8_11_2","unstructured":"Nederlandse Zorgautoriteit (NZa): Tarieventabel DBC-zorgproducten en overige-zorgproducten [in Dutch] 2019. https:\/\/puc.overheid.nl\/nza\/doc\/PUC_236092_22\/1\/"},{"key":"e_1_3_8_12_2","unstructured":"Zorginstituut Nederland (ZiNL): Medicijnkosten.nl [in Dutch]. https:\/\/www.medicijnkosten.nl\/"},{"key":"e_1_3_8_13_2","unstructured":"Nederlandse Vereniging van Ziekenhuizen (NVZ): Prijsindexcijfers van het Centraal Planbureau [in Dutch]. https:\/\/nvz-ziekenhuizen.nl\/diensten\/prijsindexcijfers"},{"key":"e_1_3_8_14_2","unstructured":"Drugs.com: Drug price guide (Avastin Zejula Lynparza). https:\/\/www.drugs.com\/price-guide\/"},{"key":"e_1_3_8_15_2","unstructured":"Centraal Bureau van Statistiek: Consumentenprijzen; prijsindex [in Dutch]. https:\/\/opendata.cbs.nl\/statline\/#\/CBS\/nl\/dataset\/83131NED\/table?ts=1712581831160"},{"key":"e_1_3_8_16_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.ygyno.2023.01.030"},{"key":"e_1_3_8_17_2","unstructured":"Nederlandse Zorgautoriteit (NZa): Pakketadvies olaparib (Lynparza\u00ae) voor de onderhoudsbehandeling van eierstokkanker [in Dutch] 2020. https:\/\/www.zorginstituutnederland.nl\/publicaties\/adviezen\/2020\/03\/19\/pakketadvies-olaparib-lynparza"},{"key":"e_1_3_8_18_2","unstructured":"Nederlandse Zorgautoriteit (NZa): Pakketadvies niraparib (Zejula\u00ae) bij eierstokkanker [in Dutch] 2021. https:\/\/www.zorginstituutnederland.nl\/documenten\/2021\/06\/24\/pakketadvies-niraparib-zejula"},{"key":"e_1_3_8_19_2","volume-title":"Richtlijnendatabase","author":"Nederlandse Vereniging voor Obstetrie en Gynaecologie","unstructured":"Nederlandse Vereniging voor Obstetrie en Gynaecologie: Bevacizumab bij de primaire behandeling van stadium III\u2013IV epitheliaal ovariumcarcinoom. Richtlijnendatabase. [in Dutch] https:\/\/richtlijnendatabase.nl\/richtlijn\/ovariumcarcinoom\/behandeling_hoog_stadium_iib_iv\/bevacizumab_bij_de_primaire_behandeling_van_stadium_iii-iv_epitheliaal_ovariumcarcinoom.html"},{"key":"e_1_3_8_20_2","doi-asserted-by":"publisher","DOI":"10.1038\/nature10166"},{"key":"e_1_3_8_21_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1810858"},{"key":"e_1_3_8_22_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1910962"},{"key":"e_1_3_8_23_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1104390"},{"key":"e_1_3_8_24_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1911361"},{"key":"e_1_3_8_25_2","doi-asserted-by":"publisher","DOI":"10.1002\/ijc.34124"},{"key":"e_1_3_8_26_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejso.2023.107084"},{"key":"e_1_3_8_27_2","unstructured":"Nederlandse Vereniging voor Medische Oncologie (NVMO): Niraparib als onderhoudsbehandeling na primaire behandeling van het gevorderd epitheliaal ovariumcarcinoom [in Dutch]. https:\/\/www.nvmo.org\/bom\/herbeoordeling-2-niraparib-als-onderhoudsbehandeling-na-primaire-behandeling-van-het-gevorderd-epitheliaal-ovariumcarcinoom\/"},{"key":"e_1_3_8_28_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.annonc.2024.08.2241"},{"key":"e_1_3_8_29_2","unstructured":"Tesaro Inc: Zejula (niraparib) tablets 2020. https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2020\/208558s013lbl.pdf"},{"key":"e_1_3_8_30_2","unstructured":"AstraZeneca Pharmaceuticals LP: Lynparza (olaparib) tablets 2019. https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2019\/208447s014lbl.pdf"},{"key":"e_1_3_8_31_2","doi-asserted-by":"publisher","DOI":"10.1136\/ijgc-2020-001640"},{"key":"e_1_3_8_32_2","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(18)30566-7"},{"key":"e_1_3_8_33_2","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2025.43.17_suppl.LBA5500"},{"key":"e_1_3_8_34_2","doi-asserted-by":"publisher","DOI":"10.1136\/ijgc-2019-000682"},{"key":"e_1_3_8_35_2","doi-asserted-by":"publisher","DOI":"10.1136\/ijgc-2020-001231"},{"key":"e_1_3_8_36_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.esmoop.2021.100098"},{"key":"e_1_3_8_37_2","doi-asserted-by":"publisher","DOI":"10.1136\/ijgc-2020-001550"},{"key":"e_1_3_8_38_2","unstructured":"Centraal Planbureau (CPB): Uitsplitsing van de inflatie in Nederland [in Dutch] 2023. https:\/\/www.cpb.nl\/sites\/default\/files\/omnidownload\/CPB-PUBLICATIE-Uitsplitsing-van-de-inflatie-in-Nederland.pdf"},{"key":"e_1_3_8_39_2","doi-asserted-by":"publisher","DOI":"10.1136\/ijgc-2020-001403"},{"key":"e_1_3_8_40_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.ygyno.2019.01.025"},{"key":"e_1_3_8_41_2","doi-asserted-by":"publisher","DOI":"10.1007\/s10198-024-01673-3"},{"key":"e_1_3_8_42_2","unstructured":"Ministerie van Volksgezondheid Welzijn en Sport; E.J. Kuipers: Naar een toekomstbestendig stelsel voor de vergoeding van nieuwe dure geneesmiddelen uit het basispakket [in Dutch]. https:\/\/www.tweedekamer.nl\/debat_en_vergadering\/commissievergaderingen\/details?id=2023A05417"}],"container-title":["JCO Oncology Practice"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/ascopubs.org\/doi\/pdfdirect\/10.1200\/OP-25-00670","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,12,19]],"date-time":"2025-12-19T20:59:49Z","timestamp":1766177989000},"score":1,"resource":{"primary":{"URL":"https:\/\/ascopubs.org\/doi\/10.1200\/OP-25-00670"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,12,19]]},"references-count":41,"alternative-id":["10.1200\/OP-25-00670"],"URL":"https:\/\/doi.org\/10.1200\/op-25-00670","relation":{},"ISSN":["2688-1527","2688-1535"],"issn-type":[{"value":"2688-1527","type":"print"},{"value":"2688-1535","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,12,19]]},"assertion":[{"value":"2025-07-03","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2025-09-30","order":1,"name":"revised","label":"Revised","group":{"name":"publication_history","label":"Publication History"}},{"value":"2025-11-14","order":2,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2025-12-19","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}],"article-number":"OP-25-00670"}}